Inclusion Criteria:

   - Part 1: Histologically or cytologically confirmed, locally advanced or metastatic,
   treatment-refractory solid tumors

   - Part 2: Histologically or cytologically confirmed, locally advanced or metastatic:
   NSCLC (squamous or non-squamous cell carcinoma; up to 2 prior treatment regimens),
   Colorectal Cancer (up to 2 prior treatment regimens), Pancreatic Cancer (up to 1 prior
   treatment regimen), Ovarian cancer (up to 2 prior treatment regimens), or Sarcoma (up
   to 2 prior treatment regimens), according to cohort availability

   - Eastern Cooperative Group (ECOG performance status of 0 or 1

   - Women or men ≥16 years of age

   - Adequate hematology, renal, hepatic, coagulation and glycemic function.

Exclusion Criteria:

   - Presence of uncontrolled central nervous system (CNS) disease

   - Systemic chemotherapy, hormonal therapy, immunotherapy, experimental or approved
   anticancer proteins/antibodies therapy ≤28 days before enrollment.

   - Prior treatment with death receptor agonists (including but not limited to
   rhApo2L/TRAIL [AMG951], apomab, mapatumumab, lexatumumab, CS-1008)

   - Prior treatment with IGF receptor antagonists (including but not limited to CP-751,
   871, MK0646, AVE1642 or IMC-A12)